Boston Scientific's Growth Engines Stumble: WATCHMAN and EP Pressures Trigger Guidance Cut and Restructuring
Q2 beat masked by lowered FY26 outlook, restructuring plan, and 2027 caution as LAAC and PFA face competitive and clinical headwinds.
BSX-PA · Earnings Call · 2026-07-29
A Beat Masked by a Lowered Bar
Boston Scientific reported a solid Q2 2026, with organic sales up 7% and adjusted EPS of $0.86 beating the high end of guidance. Yet the market's attention quickly turned to the company's decision to cut full-year 2026 revenue guidance to 5-6% and EPS to $3.28-3.32 (7-8% growth), citing accelerating pressure in two of its most celebrated growth franchises. As CEO Mike Mahoney noted, “Second quarter represented a solid quarter for Boston Scientific, while we continue to navigate a dynamic environment.” — Michael Mahoney, Chairman and Chief Executive Officer · 2026-07-29 The tension between the beat and the reduced outlook sets the stage for a pivotal inflection point in the company's trajectory.
WATCHMAN: A Market Slowing Faster Than Expected
The LAAC (left atrial appendage closure) market, dominated by WATCHMAN, has been hit by a confluence of clinical evidence and reimbursement changes. U.S. growth slowed to 3% in Q2, international growth of 18% provided some offset, but the full-year guidance now calls for flat to low-single-digit growth. Mahoney explained, “The challenge, as you know, has been in the 2 areas, EP and WATCHMAN, that had hyper growth... and now we expect more pressure in '26 and '27.” — Michael Mahoney, Chairman and Chief Executive Officer · 2026-07-29 The company attributes the slowdown to published trial data (OCEAN, CHAMPION) affecting referral patterns, and a rapid shift to concomitant procedures (now one-third of U.S. procedures) creating operational inefficiencies. Notably, stand-alone procedure volumes declined in the low-teens. Management is not assuming any near-term improvement, even as they invest in education and commercial expansion.
We absolutely believe in this therapy and that WATCHMAN is the best treatment for patients who can't, won't or shouldn't take oral anticoagulation for stroke prevention. We expect that the actions we are taking today will support the LAAC market over time. However, we are not assuming improved WATCHMAN growth in 2027 until we see these dynamics actually change.
EP: Competitive Share Loss in a Hyper-Growth Market
Electrophysiology (EP) has been another growth engine, but competitive pressure in the U.S. is eroding share. While international EP grew 23% and the portfolio remains innovative, U.S. growth was just 3%. The PFA (pulsed field ablation) market has accelerated to ~80-85% of AFib procedures, limiting the ability to offset competitive launches. Mahoney candidly admitted, “We did undercall the competitive pressures in the U.S. in terms of share taking. We continue to be the PFA leader, but our share has come down.” — Michael Mahoney, Chairman and Chief Executive Officer · 2026-07-29 Full-year global EP growth is now expected to be flat in the second half, with improvement deferred to 2027-2028 upon the launch of FARAWAVE Ultra and entry into the ICE market. The company is also prioritizing its 75% of revenue growing ~6%, aiming to reaccelerate once these product cycles mature.
Restructuring for a 2028 Rebound
In response, Boston Scientific announced a company-wide restructuring to deliver ~$500 million in run-rate savings by 2029. CFO Jon Monson emphasized, “We are taking decisive actions to sharpen our organizational focus, adjust our cost structure and position the business for the future.” — Jonathan Monson, Executive Vice President and Chief Financial Officer · 2026-07-29 The program will fund investments in high-growth areas like interventional cardiology, neuromodulation, and the Earnings growth restoration. The company also cited IEEPA refunds and tariff-related tailwinds that partially offset pressures, but the core issue remains the tariff refund is not enough to stem top-line deceleration. Looking ahead, management guided to limited EPS growth in 2027, but expects 2028 to be a year of reacceleration driven by seven major launches (IVL, TAVR, renal denervation, etc.) and a strengthened base business. As Mahoney noted, “We expect that core 75% of our business to strengthen over that time period... and we feel like the combination of all those elements will drive us to high performance again in '28 and beyond.” — Michael Mahoney, Chairman and Chief Executive Officer · 2026-07-29
This is a pivotal moment for Boston Scientific. The company is navigating a rare double hit in its two fastest-growing franchises, forcing a recalibration of growth expectations. While the long-term thesis remains intact, the near-term path is more volatile than investors have come to expect, making this report a must-read for anyone tracking the medical device sector.